


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

**Claim 1. (currently amended)** A compound having the ~~general~~ formula (I) shown below,



[[[]]]wherein,

$\text{R}^1$  represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of  $\text{C}_1\text{-C}_4$  alkoxy groups and  $\text{C}_1\text{-C}_4$  halogenated alkyl groups;

$\text{R}^2$  represents a phenyl group substituted with from 1 to 3 halogen atoms;

$\text{R}^3$  represents a phenyl group substituted with a halogen atom or a nitro group;

$\text{D}$  represents an oxygen atom or a methylene group, and

$n$  represents an integer of 0 or 1[[[]]].

**Claim 2. (currently amended)** A compound according to Claim 1, wherein  $\text{R}^1$  is 3-isopropyloxy isopropyloxyphenyl, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

**Claim 3. (original)** A compound according to Claim 1, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

**Claim 4. (currently amended)** A compound according to ~~any one claim selected from Claims~~ Claim 1 ~~[[to 3]]~~, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

**Claim 5. (currently amended)** A compound according to ~~any one claim selected from Claims~~ Claim 1 ~~[[to 3]]~~, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

**Claim 6. (currently amended)** A compound according to ~~any one claim selected from Claims~~ Claim 1 ~~[[to 5]]~~, wherein D is an oxygen atom.

**Claim 7. (currently amended)** A compound according to ~~any one claim selected from Claims~~ Claim 1 ~~[[to 6]]~~, wherein n is 0.

**Claim 8. (currently amended)** A compound according to Claim 1, wherein R<sup>1</sup> is 3-isopropoxy isopropoxyphenyl, D is a methylene group, and n is 1.

Claim 9. (currently amended) A compound according to ~~any one claim selected from Claims Claim 1~~ Claim 1 ~~[[to 8]]~~, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

Claim 10. (currently amended) A compound according to Claim 1, wherein ~~[[the]]~~ said compound is ~~any one of the compounds listed below~~ selected from the group consisting of

[[•]]2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]]2-[[[2-]]{3[[[4-]]dichlorophenyl}[[[4-]]{3[[[4,5-]]trimethoxybenzoyl}morpholin-2-yl]ethyl}[[4-]]chlorobenzenesulfonate[[,]]

[[•]]2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,

[[•]]2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,

[[•]]2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]]2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,

[[•]]2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,

[[•]]2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]]2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,

[[•]]2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]]2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]]2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]]2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]]2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]]2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]]2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]]2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]]2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and  
 [[•]]2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.

**Claim 11. (currently amended)** A compound according to Claim 1, wherein [[the]] said compound is ~~any one of the compounds listed below~~ selected from the group consisting of



[[•]]2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]]2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]]2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]] 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

[[•]] 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate, and

[[•]] 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 12. (currently amended)** A compound, having an enantiomeric excess which is substantially 100%, having the ~~general~~ formula (I') or (I'') shown below,



[[()]]wherein

R<sup>1</sup> represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkoxy groups and C<sub>1</sub>-C<sub>4</sub> halogenated alkyl groups;

R<sup>2</sup> represents a phenyl group substituted with from 1 to 3 halogen atoms;

R<sup>3</sup> represents a phenyl group substituted with a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group, and

n represents an integer of 0 or 1[[()]].

Claim 13. (currently amended) A compound according to Claim 12, wherein R<sup>1</sup> is 3-~~isopropoxy~~ isopropoxyphenyl, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

Claim 14. (original) A compound according to Claim 12, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

Claim 15. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 14]]~~, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

Claim 16. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 14]]~~, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

Claim 17. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 16]]~~, wherein D is an oxygen atom.

Claim 18. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 17]]~~, wherein n is 0.

Claim 19. (currently amended) A compound according to Claim 12, wherein R<sup>1</sup> is 3-~~isopropyloxy~~ isopropoxyphenyl, D is a methylene group, and n is 1.

Claim 20. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 19]]~~, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

Claim 21. (currently amended) A compound according to ~~any one claim selected from Claims~~ Claim 12 ~~[[to 20]]~~, having the ~~general~~ formula (I').

Claim 22. (currently amended) A compound according to Claim 12, wherein ~~[[[the]] said compound is any one of the compounds listed below~~ [[[:]] is selected from the group consisting of

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,

[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,

[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-



dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.

**Claim 23. (currently amended)** A compound according to Claim 12, wherein [[the]] said compound is ~~any one of the compounds listed below~~[[:]] selected from the group consisting of



[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[3-[3,5-bis(trifluoromethyl)benzoyl]-1-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 24. (currently amended)** A method for obtaining a compound, having an enantiomeric excess which is substantially 100%, having the ~~general~~ formula (I') or (I'') [[by]] comprising crystallizing a mixture of a compound having the ~~general~~ formula (I') and a compound having the ~~general~~ formula (I''):



[[(]] wherein in the ~~general~~ formulae (I') and (I''),  
 R<sup>1</sup> represents a phenyl group substituted with 1 to 3 groups

selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkoxy groups and C<sub>1</sub>-C<sub>4</sub> halogenated alkyl groups;

R<sup>2</sup> represents a phenyl group substituted with 1 to 3 halogen atoms;

R<sup>3</sup> represents a C<sub>1</sub>-C<sub>4</sub> alkyl group, ~~[[a]]~~ an unsubstituted phenyl group, or a phenyl group substituted with a C<sub>1</sub>-C<sub>4</sub> alkyl group, a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group; and

n represents an integer of 0 or 1~~[[()]]~~.

**Claim 25. (currently amended)** A method according to Claim 24, wherein R<sup>1</sup> is 3-~~isopropoxy~~ isopropoxyphenyl, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

**Claim 26. (original)** A method according to Claim 24, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

**Claim 27. (currently amended)** A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 26]]~~, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

**Claim 28. (currently amended)** A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 26]]~~, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

Claim 29. (currently amended) A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 28]]~~, wherein R<sup>3</sup> is a methyl group, ~~[[a]]~~ an unsubstituted phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

Claim 30. (currently amended) A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 29]]~~, wherein D is an oxygen atom.

Claim 31. (currently amended) A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 30]]~~, wherein n is 0.

Claim 32. (original) A method according to Claim 24, wherein R<sup>1</sup> is 3-isopropoxyphenyl, D is a methylene group, and n is 1.

Claim 33. (currently amended) A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 32]]~~, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

Claim 34. (currently amended) A method according to ~~any one claim selected from Claims~~ Claim 24 ~~[[to 33]]~~, for obtaining a

compound, having an enantiomeric excess which is substantially 100%, having the ~~general~~ formula (I').

**Claim 35. (currently amended)** A method according to Claim 24, ~~for obtaining any one of the compounds listed below~~[[::]] wherein the compound obtained is selected from the group consisting of

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,  
[[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,


[[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate, and  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate.

**Claim 36. (currently amended)** A method according to Claim 24,  
~~for obtaining any one of the compounds listed below~~[[:]]


[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

[[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

Claim 37. (currently amended) A method for preparing ~~compounds~~ a compound having ~~general~~ formula (III) shown below or a pharmaceutically acceptable ~~salts~~ salt thereof, ~~which is characterized by comprising~~ reacting a compound having ~~general~~ formula (I') shown below with a compound having ~~general~~ formula (II) shown below:



[[[]]wherein R<sup>1</sup> represents a phenyl group substituted with 1 to 3 substituents selected from [[a]] the group consisting of C<sub>1</sub>-C<sub>4</sub> alkoxy groups and C<sub>1</sub>-C<sub>4</sub> halogenated alkyl groups; R<sup>2</sup> represents a phenyl group substituted with 1 to 3 halogen atoms; R<sup>3</sup> represents [[a]] an unsubstituted phenyl group or a phenyl group substituted with a C<sub>1</sub>-C<sub>4</sub> alkyl group, a halogen atom or a nitro group; D represents an oxygen atom or a methylene group; and n represents an integer of 0 or 1[[[]]],



and;



```
hereinbefore[[]]).
```

bis(trifluoromethyl)phenyl.

is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

~~claim selected from Claims Claim 37 [[to 39]], wherein R<sup>2</sup> is a~~

~~claim selected from Claims~~ Claim 37 ~~[[to 39]]~~, wherein R<sup>2</sup> is

Claim 42. (currently amended) A method according to ~~any one claim selected from Claims Claim~~ 37 ~~[[to 41]]~~, wherein R<sup>3</sup> is ~~[[a]]~~ an unsubstituted phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

Claim 43. (currently amended) A method according to ~~any one claim selected from Claims Claim~~ 37 ~~[[to 42]]~~, wherein D is an oxygen atom.

Claim 44. (currently amended) A method according to ~~any one claim selected from Claims Claim~~ 37 ~~[[to 43]]~~, wherein n is 0.

Claim 45. (original) A method according to Claim 37, wherein R<sup>1</sup> is 3-isopropoxyphenyl, D is a methylene group, and n is 1.

Claim 46. (currently amended) A method according to ~~any one claim selected from Claims Claim~~ 37 ~~[[to 45]]~~, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

Claim 47. (currently amended) A method according to Claim 37, wherein the ~~compounds~~ compound having ~~general~~ formula (I') is ~~any~~



~~one of the compounds listed below~~[[:]] selected from the group consisting of

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,  
[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl benzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,

[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,  
 [[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl benzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,  
 [[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate, and  
 [[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate.

**Claim 48. (currently amended)** A method according to Claim 37, wherein the ~~compounds~~ compound having ~~general~~ the formula (I') is ~~any one of the compounds listed below~~ selected from the group consisting of

[[•]] (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,  
[[•]] (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and  
[[•]] (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 49. (new)** A compound according to Claim 1, wherein the compound is 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 50. (new)** A compound according to Claim 1, wherein the compound is 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 51. (new)** A compound according to Claim 12, wherein the compound is (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

**Claim 52. (new)** A compound according to claim 12, wherein the compound is (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.